It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Dallas Fed President Robert Kaplan would like to avoid additional stimulus but is keeping an "open mind."The Fedread more
Overstock CEO Partick Byrne has resigned from the e-commerce company after making comments about his role in the "deep state."Technologyread more
It was the third trigger of the recession indicator in less than two weeks.Bondsread more
Automakers are trying to deal with President Trump's efforts to roll back Obama-era fuel efficiency rules.Autosread more
Mark Zuckerberg has been on a selling spree in August and has unloaded $526 million worth of stock this year.Technologyread more
Palantir CEO Alex Karp said billionaire investor Peter Thiel is right to question Google's decision to work in China, while abandoning military contracts in the US.Technologyread more
These are the stocks posting the largest moves midday.Market Insiderread more
U.S. manufacturer growth slowed to the lowest level in almost 10 years in August, the latest sign that the trade war may be exacerbating the economic slowdown.Marketsread more
(Adds details, shares, estimates)
July 30 (Reuters) - Eli Lilly and Co beat analysts' estimates for quarterly profit on Tuesday and raised its full-year earnings forecast, as higher sales of diabetes drugs Trulicity and Basaglar offset competition for its erectile dysfunction drug, Cialis.
Trulicity accounted for 18% of the company's total sales in the second quarter and brought in $1.03 billion, just above the average analyst estimate of $1.02 billion, according to IBES data from Refinitiv.
The company raised its 2019 adjusted earnings forecast to a range of $5.67 to $5.77 per share from its prior range of $5.60 to $5.70 per share .
However, revenue from the United States was nearly flat at $3.25 billion, mainly due to lower prices even as volumes rose.
The drugmaker posted net income of $1.33 billion, or $1.44 per share, in the quarter ended June 30, compared with a loss of $259.9 million, or 25 cents per share, when it recorded acquisition-related charges of $1.62 billion.
Excluding items, Lilly earned $1.5 per share. Analysts on average had expected a profit of $1.45 per share, according to IBES data from Refinitiv.
Revenue rose to $5.64 billion from $5.59 billion, above Wall Street estimates of $5.59 billion.
Shares of the company rose 1.1% to $109.89 in early trading before the bell. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Anil D'Silva)